Safety aspects of subcutaneous immunotherapy with multiple allergens--a retrospective analysis on polysensitized patients.
Polysensitization against a multitude of different allergens is a common problem in the treatment of allergies with specific immunotherapy (SIT). The aim of this retrospective study was to investigate the risk of simultaneous administration of two allergen extracts during SIT with a conventional or Cluster regimen. Local (LR) and systemic reactions (SR) in 147 patients receiving different forms of SIT were compared. Patients received a total number of 2,758 injections during dose-increase phase and 3,412 injections during maintenance phase. During dose-increase phase, a higher rate of LR (for 1A 0.7% and for 2A 1.5%) was found with parallel injections of two allergen extracts (2A). The increase of SR was, however, not significant with conventional (for 1A 0% and for 2A 0.3%) or Cluster therapy (for 1A 0.3% and for 2A 0.5%). No increment of SR with injections of two allergen extracts did occur during maintenance phase (for 1A 0.3% and for 2A 0.1%). In conclusion, the results of the present study indicate that a higher rate of LR and SR must be considered during dose-increase phase independent of the kind of induction regime used. The rate of adverse events (AE) with two different allergen extracts, however, seems tolerable. After reaching maintenance phase, a higher rate of AE with parallel allergen injections did not occur.
Barth
C
C
Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. Christine.Barth@umm.de
Anero
F
F
Pfaar
O
O
Klimek
L
L
Hörmann
K
K
Stuck
B A
BA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000485:Allergens / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D015331:Cohort Studies; D003888:Desensitization, Immunologic / Q000009:adverse effects* / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control*; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D055815:Young Adult
D000485:Allergens
Int Arch Allergy Immunol. 2009;148(3):251-60
18849616
HNO. 2009 Nov;57(11):1099-105
19585090
N Engl J Med. 1999 Aug 12;341(7):468-75
10441602
Int Arch Allergy Immunol. 2003 Nov;132(3):258-62
14646387
Allergy. 2002 Apr;57(4):306-12
11906360
Thorax. 1999 Aug;54(8):675-80
10413718
J Allergy Clin Immunol. 2006 Jan;117(1):169-75
16387602
Eur Arch Otorhinolaryngol. 2010 Feb;267(2):245-50
19756683
Int J Epidemiol. 1986 Jun;15(2):202-9
3721682
Allergy. 2000 Sep;55(9):827-35
11003446
Laryngorhinootologie. 2003 Aug;82(8):558-63
12915987
Pediatr Allergy Immunol. 2008 Feb;19(1):67-75
17651380
J Investig Allergol Clin Immunol. 2004;14(4):312-9
15736717
Int Arch Allergy Immunol. 2001 May;125(1):57-65
11385289
Allergy. 2003 Dec;58(12):1261-7
14616101
J Allergy Clin Immunol. 1998 Oct;102(4 Pt 1):558-62
9802362
Clin Exp Allergy. 2007 Mar;37(3):434-40
17359393
Ann Allergy. 1960 Apr;18:427-34
13824740
J Allergy Clin Immunol. 2005 Jul;116(1):109-18
15990782
J Investig Allergol Clin Immunol. 2003;13(4):221-7
14989109
Eur Ann Allergy Clin Immunol. 2004 Feb;36(2):52-5
15061395
Clin Exp Allergy. 2004 Apr;34(4):527-31
15080803
Clin Exp Allergy. 2006 Apr;36(4):503-9
16630156
Clin Exp Allergy. 2002 Dec;32(12):1745-9
12653166
Allergy. 1993 Aug;48(6):450-3
8238801
Thorax. 2002 Oct;57 Suppl 2:II36-II39
12364709
J Allergy Clin Immunol. 1991 Mar;87(3):737-46
2005328
Ann Allergy Asthma Immunol. 2006 Aug;97(2):126-37; quiz 137-40, 202
16937741
Hautarzt. 2006 Oct;57(10):860-6
16964477
J Allergy Clin Immunol. 2002 Feb;109(2):251-6
11842293
Int Arch Allergy Immunol. 2009;150(1):102-8
19339808
Hautarzt. 2006 Oct;57(10):875-80
16969674
Int Arch Allergy Immunol. 2009;148(2):161-9
18802361
Clin Exp Allergy. 2006 Mar;36(3):254-60
16499635